ChemoCentryx, Inc. (CCXI)
| Previous Close | 39.52 |
| Open | 39.38 |
| Bid | 38.70 x 1100 |
| Ask | 39.50 x 2200 |
| Day's Range | 38.43 - 39.79 |
| 52 Week Range | 9.53 - 70.29 |
| Volume | |
| Avg. Volume | 4,914,246 |
| Market Cap | 2.753B |
| Beta (5Y Monthly) | 1.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings Date | Feb. 28, 2022 - Mar. 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.50 |
- Simply Wall St.
ChemoCentryx's (NASDAQ:CCXI) investors will be pleased with their incredible 382% return over the last five years
Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock...
- Zacks
ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos
ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.
- GlobeNewswire
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the Company’s TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, in combination with a rituximab or cyclophosphamide regimen, indicated for the treatment of adult patients with severe, active g
